Fed. Circ. Nixes Injunction On Mylan's Generic Doryx

Law360, New York (December 12, 2011, 3:45 PM EST) -- The Federal Circuit on Monday vacated an injunction barring Mylan Pharmaceuticals Inc. from producing a generic version of oral antibiotic Doryx while Warner Chilcott LLC pursues a patent infringement suit over the company's abbreviated new drug application.

Warner Chilcott filed suit in May 2009, claiming Mylan's plans to market a generic Doryx in 150-milligram delayed-release tablets infringed its patent for the drug, which is used to treat acne. In September, U.S. District Judge William Martini granted Warner's request for a preliminary injunction, finding the Irish drug...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.